Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.
about
Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learningNicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: effects of the cannabinoid receptor 1 antagonist AM251The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in ratsVoluntary exercise offers anxiolytic potential and amplifies galanin gene expression in the locus coeruleus of the rat.Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxiety-related structures.Endocannabinoids and striatal function: implications for addiction-related behaviours2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspectiveThe novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behaviorCentral mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in ratsEndocannabinoid Signaling in the Stress Response of Male and Female SongbirdsChanges in nucleus accumbens and neostriatal c-Fos and DARPP-32 immunoreactivity during different stages of food-reinforced instrumental training.Elucidating cannabinoid biology in zebrafish (Danio rerio).Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach.Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.Neuroanatomical substrates involved in cannabinoid modulation of defensive responses.CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.The vital role of constitutive GPCR activity in the mesolimbic dopamine system.Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel MonkeysEvaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model.CB1 receptor signaling regulates social anxiety and memory.Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain.
P2860
Q26269894-04EF3B30-3207-457E-B551-7CC0437BA501Q28564481-F43EAC1C-05A1-4D45-8614-0084DF8EDA4BQ30355922-A63ADE35-FB94-436F-9DD1-09D3790448FBQ30452222-290212EF-1EA0-4431-B371-A508AB06B0D4Q30474610-67E71552-357A-4746-AEB8-5CD2253099F6Q33583792-0050E24F-6E1E-4C1A-B143-BC2825F01381Q33781776-3B0FF27B-1F6F-432C-A8EC-BA9DFADEB1DEQ34131412-DA77588E-54D4-48B2-96D3-5A9CC8F64CF9Q34168253-74B41B8C-E728-44FF-A094-3769976B9DAEQ36305128-AAE38A27-8B62-4337-9793-F4E690117F17Q36466166-374E90D2-4F4A-45D6-A4AC-47C743477540Q37090161-E9F1AD03-6DB2-4F2A-9B37-A05C95638F00Q37728629-C648BD97-142E-49F4-80AF-0A457F8466FBQ37862977-65E783CB-8F9A-4680-A63C-361665FE2735Q37880502-3ACD1B09-FD89-4B6E-A57A-85CCFE3A4AEBQ37899264-DEF45216-B767-4ED5-8867-5C0862DA0691Q38025166-267D5C43-7C3F-4F63-B730-9DF33C5CE3BAQ38187259-C1ABABA4-7F3B-49FA-99BE-5A56714805D6Q38636791-7018AD90-8D03-4079-8DAF-BF99C50E6D79Q39459073-DC5388AD-467F-4F05-88B7-1226785DC3E0Q40446321-A3ED7C37-8527-4F7E-B199-47EA1B42F291Q41873288-4A618815-F4FE-41AF-8025-B9754464D72AQ41907106-E4BA35B0-2303-476E-B919-D5643EE6C3DCQ42961232-A07504DF-BE7C-4038-B411-3828D3513C24Q45288843-DFA3E47C-9B4A-426A-8407-AFA113AB16B9Q47647272-6CB18265-3A64-4B0E-9C4F-7D82E4D9EF87Q47950160-B0F31EA9-D54B-4689-98AD-C057FC51F0A6Q48018603-6A7C19F4-E4FF-4B1A-93ED-872FC68667E5Q48022869-2FB95A5B-6AF2-4E4F-A957-0274CA17E987Q48337573-D5A4D78D-0F3F-45A3-8672-38D36A50A5A0
P2860
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@ast
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@en
type
label
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@ast
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@en
prefLabel
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@ast
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@en
P2093
P2860
P921
P1476
Potential anxiogenic effects o ...... epine inverse agonist FG-7142.
@en
P2093
E J Markus
J D Salamone
K N Segovia
L E Collins
P A Randall
V K Vemuri
P2860
P304
P356
10.1016/J.EURONEURO.2009.11.002
P407
P577
2009-12-16T00:00:00Z